AVITA MEDICAL INCRCEL
ASignal's systematic analysis rates RCEL as Bearish.
Reflects the latest available analysis · analyzed Oct 9, 2026
The case on RCEL
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong gross margin (81.56%) indicating pricing power
- Revenue growth of 17.8% year-over-year
- MACD above signal line with expanding histogram, suggesting strengthening momentum
- Price above 20-day and 50-day moving averages
- RSI at 72.78, indicating overbought conditions
- Negative profit margin (-56.96%) and operating margin (-31.59%)
- Negative return on assets (-41.56%)
- Current ratio (0.41x) and quick ratio (0.31x) suggest liquidity concerns
- High beta (1.99x) indicating elevated volatility risk
- Negative free cash flow (-$13.35M) and operating cash flow (-$24.23M)
See the full verdict on RCEL
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes RCEL
Most investors never get a second opinion, let alone several. ASignal runs RCEL past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.